Naftifine HClAllylamine antifungal agent CAS# 65473-14-5 |
- Leupeptin, Microbial
Catalog No.:BCC1217
CAS No.:103476-89-7
- BCX 1470
Catalog No.:BCC1413
CAS No.:217099-43-9
- BCX 1470 methanesulfonate
Catalog No.:BCC1414
CAS No.:217099-44-0
- PMSF
Catalog No.:BCC1229
CAS No.:329-98-6
- Nafamostat hydrochloride
Catalog No.:BCC4188
CAS No.:80251-32-7
- Nafamostat
Catalog No.:BCC4187
CAS No.:81525-10-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 65473-14-5 | SDF | Download SDF |
PubChem ID | 5281098 | Appearance | Powder |
Formula | C21H22ClN | M.Wt | 323.86 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 100 mg/mL (308.78 mM; Need ultrasonic) Ethanol : 25 mg/mL (77.19 mM; Need ultrasonic) | ||
Chemical Name | (E)-N-methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine;hydrochloride | ||
SMILES | [H+].[Cl-].CN(CC=Cc1ccccc1)Cc2cccc3ccccc23 | ||
Standard InChIKey | OLUNPKFOFGZHRT-YGCVIUNWSA-N | ||
Standard InChI | InChI=1S/C21H21N.ClH/c1-22(16-8-11-18-9-3-2-4-10-18)17-20-14-7-13-19-12-5-6-15-21(19)20;/h2-15H,16-17H2,1H3;1H/b11-8+; | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Naftifine HCl Dilution Calculator
Naftifine HCl Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.0878 mL | 15.4388 mL | 30.8775 mL | 61.7551 mL | 77.1938 mL |
5 mM | 0.6176 mL | 3.0878 mL | 6.1755 mL | 12.351 mL | 15.4388 mL |
10 mM | 0.3088 mL | 1.5439 mL | 3.0878 mL | 6.1755 mL | 7.7194 mL |
50 mM | 0.0618 mL | 0.3088 mL | 0.6176 mL | 1.2351 mL | 1.5439 mL |
100 mM | 0.0309 mL | 0.1544 mL | 0.3088 mL | 0.6176 mL | 0.7719 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Naftifine is an allylamine antifungal drug for the topical treatment of tinea pedis, tinea cruris, and tinea corporis, probably involves selectively blocking sterol biosynthesis via inhibition of the squalene 2,3-epoxidase enzyme.
- (Z)-23-Coumaroylhederagenin
Catalog No.:BCN3748
CAS No.:654678-61-2
- Sitagliptin phosphate
Catalog No.:BCC9148
CAS No.:654671-78-0
- Sitagliptin phosphate monohydrate
Catalog No.:BCC2111
CAS No.:654671-77-9
- Fmoc-Asn(Trt)-ol
Catalog No.:BCC2585
CAS No.:654670-89-0
- Acantrifoic acid A
Catalog No.:BCN6488
CAS No.:654663-85-1
- Phebalosin
Catalog No.:BCN4198
CAS No.:6545-99-9
- 1-Methoxyphaseollidin
Catalog No.:BCN7185
CAS No.:65428-13-9
- DL-Dab.2HCl
Catalog No.:BCC2669
CAS No.:65427-54-5
- Boc-Asn(Xan)-OH
Catalog No.:BCC3361
CAS No.:65420-40-8
- H-D-Asp-Ome
Catalog No.:BCC2896
CAS No.:65414-78-0
- Altholactone
Catalog No.:BCN4786
CAS No.:65408-91-5
- Morin hydrate
Catalog No.:BCC8214
CAS No.:654055-01-3
- Esculentoside A
Catalog No.:BCN5010
CAS No.:65497-07-6
- Cyclo(Pro-Ala)
Catalog No.:BCN2427
CAS No.:65556-33-4
- Europine N-oxide
Catalog No.:BCN1977
CAS No.:65582-53-8
- 1-Hydroxyacridone
Catalog No.:BCN7524
CAS No.:65582-54-9
- 4'-Demethylepipodophyllotoxin
Catalog No.:BCN5918
CAS No.:6559-91-7
- Cerbinal
Catalog No.:BCN4199
CAS No.:65597-42-4
- Cerberic acid
Catalog No.:BCN4200
CAS No.:65597-44-6
- Ophiopogonin D'
Catalog No.:BCN2645
CAS No.:65604-80-0
- Nintedanib (BIBF 1120)
Catalog No.:BCC3661
CAS No.:656247-17-5
- Fenretinide
Catalog No.:BCC1572
CAS No.:65646-68-6
- Esculentoside E
Catalog No.:BCN5014
CAS No.:65649-36-7
- Silybin B maltoside
Catalog No.:BCC8250
CAS No.:335299-49-5
Efficacy and safety of naftifine HCl Gel 2% in the treatment of interdigital and moccasin type tinea pedis: pooled results from two multicenter, randomized, double-blind, vehicle-controlled trials.[Pubmed:23986165]
J Drugs Dermatol. 2013 Aug;12(8):911-8.
BACKGROUND: Tinea pedis is the most common chronic fungal infection. Naftifine hydrochloride is a topical antifungal of the allylamine class, displaying fungicidal activity and clinically significant anti-bacterial and anti-inflammatory effects. OBJECTIVE: To evaluate the efficacy and safety of two-weeks once daily application of naftifine gel 2% in the treatment of tinea pedis. METHODS: At baseline, 1715 subjects were randomly assigned 2:1 to naftifine gel 2% (n=1144) and vehicle (n=571). Efficacy consisting of mycologic determination (KOH and dermatophyte cultures) and scoring of clinical symptom severity was evaluated at baseline and weeks 2, 4, and 6. Efficacy was analyzed in 1174 subjects (n=782, naftifine; n=392, vehicle) with a positive baseline dermatophyte culture and KOH for whom week 6 assessments were available. Safety was evaluated by adverse events (AE) and laboratory values in 1714 subjects (n=1143, naftifine; n=571, vehicle). RESULTS: Subjects treated with naftifine gel 2% for interdigital-type tinea pedis demonstrated greater improvement from baseline for complete cure (P=0.001), mycological cure (P<0.0001), and treatment effectiveness (P<0.0001) as early as 2 weeks when compared to vehicle; however the highest response rates were seen 4-weeks post treatment (P<0.0001, for all endpoints). Statistically significant results for complete cure, mycological cure, and treatment effectiveness (P<0.0001, for all endpoints) were also seen at week 6 among subjects with moccasin-type tinea pedis. Treatment related adverse events were minimal. CONCLUSIONS: Treatment with naftifine gel 2% applied once daily for two weeks is well-tolerated and is effective in treating both interdigital-type and moccasin-type tinea pedis. Continuous improvement is observed from the end of treatment to four-weeks after treatment cessation among key outcome measures (complete cure, mycological cure, and treatment effectiveness) as well as clinical signs and symptoms (erythema, scaling, and pruritus)
The Role of Naftifine HCl 2% Gel and Cream in Treating Moccasin Tinea Pedis.[Pubmed:26885800]
J Drugs Dermatol. 2016 Feb;15(2 Suppl):s56-9.
In recent years, new topical antifungals have emerged for the treatment and management of tinea pedis, but all have been investigated and approved for the treatment of interdigital tinea pedis. Moccasin tinea pedis has not been recognized by governing bodies as a definable and treatable disease entity separate from interdigital tinea pedis at this time. Thus, creating randomized, controlled clinical trials to investigate moccasin tinea pedis is a challenge without an agreed upon definition of the disease state, treatment regimen, and treatment course. Considering systemic therapy issues and the lack of data from large trials demonstrating safety and efficacy in the topical management of this clinical presentation, an unmet need has been created for a topical antifungal agent that can treat moccasin tinea pedis. Naftifine 2% gel, an allylamine, was studied in a clinical trial that enrolled patients who had interdigital or both interdigital and moccasin-type tinea pedis. In the moccasin group, the primary efficacy endpoint of complete cure at week 2 (end of treatment) was 1.7% (gel) vs 0.9% (vehicle) and week 6 (four weeks post-treatment) was 19.2% (gel) vs 0.9% (vehicle). Naftifine 2% cream in combination with urea 39% also showed improvement in hyperkeratotic moccasin tinea pedis.
Efficacy and Safety of Naftifine HCl Cream 2% in the Treatment of Pediatric Subjects With Tinea Corporis.[Pubmed:27272083]
J Drugs Dermatol. 2016 Jun 1;15(6):743-8.
BACKGROUND: Tinea corporis is fungal infection of body surfaces other than the feet, groin, scalp, or beard. Naftifine hydrochloride is a topical antifungal of the allylamine class used to treat tinea corporis, displaying fungicidal activity and clinically significant anti-bacterial and anti-inflammatory effects.
OBJECTIVE: To evaluate the efficacy and safety of two-weeks once daily application of naftifine cream 2% in the treatment of tinea corporis among pediatric subjects.
METHODS: At baseline, 231 subjects were randomly assigned 1:1 to naftifine cream 2% (n=116) and vehicle (n=115). Treatment effect consisting of mycologic determination (KOH and dermatophyte cultures) and scoring of clinical symptom severity was evaluated at baseline, week 2 (end of treatment) and week 3. Efficacy was analyzed in 181 subjects (n=88, naftifine; n=93, vehicle) with a positive baseline dermatophyte culture and KOH for whom week 3 assessments were available. Safety was evaluated by adverse events (AE) and laboratory values in 231 subjects (n=116, naftifine; n=115, vehicle).
RESULTS: Children with tinea corporis treated with naftifine cream 2% demonstrated significantly greater improvements from baseline over vehicle for mycological cure (P<0.0001) and treatment effectiveness (P=0.003) as early as 2 weeks (end of treatment). Response rates continued to increase post-treatment and were the highest 1-week after completion of the therapy (P=0.003 for complete cure; and P<0.001 for mycological cure and treatment effectiveness). Treatment related adverse events were minimal.
CONCLUSIONS: Treatment with naftifine cream 2% applied once daily for two weeks was well-tolerated and was effective in treating tinea corporis in children. Further improvement was observed 1-week after treatment completion for all key outcome measures (complete cure, mycological cure, treatment effectiveness, clinical cure, and clinical success) and clinical signs and symptoms (erythema, induration, and pruritus).
J Drugs Dermatol. 2016;15(6):743-748.
An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of Naftifine HCl Gel 2% in Pediatric Subjects With Tinea Pedis.[Pubmed:26151784]
J Drugs Dermatol. 2015 Jul;14(7):686-91.
BACKGROUND: Tinea pedis is the most common superficial fungal infection. Naftifine hydrochloride is a topical antifungal of the allylamine class, displaying fungicidal activity and clinically significant anti-bacterial and anti-inflammatory effects. Clinical data on topical antifungal therapy using naftifine for tinea pedis in a pediatric population is limited. OBJECTIVE: To assess trends in efficacy, tolerability, safety, and to quantify the pharmacokinetics (PK) of topical naftifine hydrochloride gel 2% in pediatric subjects with tinea pedis. METHODS: Twenty-eight subjects (22 pediatric and 6 adult controls) were enrolled and treated in the study. Approximately 2 grams of naftifine hydrochloride gel 2% was applied to each foot (4 grams total) for subjects with tinea pedis. Pharmacokinetic blood and urine samples were collected at various time points throughout the study. Efficacy was assessed based on potassium hydroxide, dermatophyte culture, and signs and symptom results at days 7, 14, and 28. Adverse event information was collected routinely.
RESULTS: The rate and extent of systemic exposure among the pediatric and adult control subjects was low. Adverse events were minimal and were not related to treatment. Positive results were observed as early as day 7; however the proportion of subjects achieving success generally increased over time through day 28 in both treatment groups. CONCLUSIONS: Naftifine hydrochloride gel 2% was found to be well tolerated and safe. Trends in clinical benefit were observed throughout the treatment period; however, continued improvement in efficacy rates were observed during the post-treatment period.